QIAGEN and Bio-Manguinhos/Fiocruz collaborate to enhance malaria and dengue detection in Brazil’s national screening programs
QIAGEN (NYSE: QGEN) has expanded its strategic partnership with Bio-Manguinhos/Fiocruz, Brazil's leading provider of vaccines and diagnostics. The collaboration enhances Brazil's national blood screening program with advanced PCR-based molecular testing for malaria, HIV, hepatitis B, and C. Additionally, it supports epidemiological surveillance of Brazil's ongoing dengue outbreak.
The new NAT Plus platform, utilizing QIAGEN's PCR reagents, is now operational in 30 laboratories across Brazil, processing 3.5 million samples annually. This advancement significantly improves transfusional safety by detecting malaria and reducing the diagnostic window for infections. QIAGEN will provide critical molecular biology technologies, custom solutions, and comprehensive training to support this public health initiative.
QIAGEN (NYSE: QGEN) ha ampliato la sua partnership strategica con Bio-Manguinhos/Fiocruz, il principale fornitore di vaccini e diagnostica in Brasile. La collaborazione potenzia il programma nazionale di screening del sangue del Brasile con test molecolari avanzati basati su PCR per malaria, HIV, epatite B e C. Inoltre, supporta la sorveglianza epidemiologica dell'attuale epidemia di dengue in Brasile.
La nuova piattaforma NAT Plus, che utilizza i reagenti PCR di QIAGEN, è ora operativa in 30 laboratori in tutto il Brasile, elaborando 3,5 milioni di campioni all'anno. Questo progresso migliora notevolmente la sicurezza trasfusionale rilevando la malaria e riducendo il tempo diagnostico per le infezioni. QIAGEN fornirà tecnologie fondamentali di biologia molecolare, soluzioni personalizzate e formazione completa per supportare questa iniziativa di salute pubblica.
QIAGEN (NYSE: QGEN) ha ampliado su asociación estratégica con Bio-Manguinhos/Fiocruz, el principal proveedor de vacunas y diagnósticos en Brasil. La colaboración mejora el programa nacional de análisis de sangre de Brasil con pruebas moleculares avanzadas basadas en PCR para malaria, VIH, hepatitis B y C. Además, apoya la vigilancia epidemiológica del actual brote de dengue en Brasil.
La nueva plataforma NAT Plus, que utiliza los reactivos PCR de QIAGEN, ya está operativa en 30 laboratorios en todo Brasil, procesando 3,5 millones de muestras anualmente. Este avance mejora significativamente la seguridad transfusional al detectar la malaria y reducir la ventana diagnóstico para infecciones. QIAGEN proporcionará tecnologías críticas de biología molecular, soluciones personalizadas y capacitación integral para apoyar esta iniciativa de salud pública.
QIAGEN (NYSE: QGEN)은 브라질의 주요 백신 및 진단 공급자인 Bio-Manguinhos/Fiocruz와의 전략적 파트너십을 확장했습니다. 이 협력은 말라리아, HIV, B형 간염, C형 간염에 대한 PCR 기반 분자 검사를 통해 브라질의 국가 혈액 검사 프로그램을 강화합니다. 또한, 브라질의 현재 뎅기열 발생에 대한 역학 감시를 지원합니다.
QIAGEN의 PCR 시약을 사용하는 새로운 NAT Plus 플랫폼은 브라질 전역의 30개 실험실에서 운영 중이며, 매년 350만 샘플을 처리하고 있습니다. 이 발전은 말라리아를 감지하고 감염에 대한 진단 시간을 단축함으로써 수혈 안전성을 크게 향상시킵니다. QIAGEN은 이 공공 건강 이니셔티브를 지원하기 위해 중요한 분자 생물학 기술, 맞춤형 솔루션 및 종합 교육을 제공할 것입니다.
QIAGEN (NYSE: QGEN) a élargi son partenariat stratégique avec Bio-Manguinhos/Fiocruz, le principal fournisseur de vaccins et de diagnostics au Brésil. Cette collaboration renforce le programme national de dépistage sanguin du Brésil en proposant des tests moléculaires avancés basés sur la PCR pour la malaria, le VIH, l'hépatite B et C. De plus, elle soutient la surveillance épidémiologique de l'actuelle épidémie de dengue au Brésil.
La nouvelle plateforme NAT Plus, utilisant les réactifs PCR de QIAGEN, est désormais opérationnelle dans 30 laboratoires à travers le Brésil, traitant 3,5 millions d'échantillons par an. Cette avancée améliore significativement la sécurité transfusionnelle en détectant la malaria et en réduisant la fenêtre diagnostique pour les infections. QIAGEN fournira des technologies critiques en biologie moléculaire, des solutions sur mesure et une formation complète pour soutenir cette initiative de santé publique.
QIAGEN (NYSE: QGEN) hat seine strategische Partnerschaft mit Bio-Manguinhos/Fiocruz, dem führenden Anbieter von Impfstoffen und Diagnosetests in Brasilien, ausgebaut. Die Zusammenarbeit verbessert das nationale Blutuntersuchungsprogramm Brasiliens mit fortschrittlichen PCR-basierten Molekulartests auf Malaria, HIV, Hepatitis B und C. Darüber hinaus unterstützt sie die Epidemiologische Überwachung des aktuellen Dengue-Ausbruchs in Brasilien.
Die neue NAT Plus-Plattform, die die PCR-Reagenzien von QIAGEN nutzt, ist nun in 30 Labors in ganz Brasilien im Einsatz und verarbeitet 3,5 Millionen Proben jährlich. Dieser Fortschritt verbessert erheblich die Transfusionssicherheit, indem Malaria erkannt wird und das diagnostische Fenster für Infektionen verkürzt wird. QIAGEN wird wichtige Technologien der Molekularbiologie, maßgeschneiderte Lösungen und umfassende Schulungen zur Unterstützung dieser öffentlichen Gesundheitsinitiative bereitstellen.
- Expansion of strategic partnership with Bio-Manguinhos/Fiocruz, a leading Brazilian health institution
- Introduction of advanced PCR-based screening for malaria, HIV, HBV, and HCV in Brazil's national blood screening program
- Support for epidemiological surveillance of ongoing dengue outbreak in Brazil
- Deployment of NAT Plus platform across 30 laboratories, processing 3.5 million samples annually
- Potential for increased revenue through supply of critical molecular biology technologies and custom solutions
- None.
Insights
This collaboration between QIAGEN and Bio-Manguinhos/Fiocruz marks a significant advancement in Brazil's public health initiatives. The expanded PCR-based screening platform now includes malaria detection alongside HIV, HBV and HCV testing for blood donations, addressing a critical gap in the country's blood safety program. This is particularly impactful for non-endemic regions where malaria screening wasn't previously available.
The platform's ability to support dengue surveillance is crucial, given Brazil's ongoing epidemic. The unique chemistry developed jointly by QIAGEN and Bio-Manguinhos/Fiocruz for dengue detection demonstrates the power of collaborative innovation in tackling pressing public health challenges.
From a research perspective, this partnership provides valuable epidemiological data on disease prevalence and distribution, which could inform future public health strategies and resource allocation in Brazil.
This partnership expansion represents a significant market opportunity for QIAGEN in Brazil's vast public health sector. With
The inclusion of QIAGEN's solutions in Bio-Manguinhos-branded kits through private labeling is a strategic move that could lead to increased market penetration and brand recognition within Brazil's healthcare system. This model could serve as a template for similar partnerships in other emerging markets, potentially driving QIAGEN's global expansion in public health sectors.
Moreover, the success of this collaboration in addressing critical public health needs may strengthen QIAGEN's position in future government contracts and partnerships, both in Brazil and other countries facing similar challenges.
While specific financial figures aren't provided, this expanded partnership likely represents a significant revenue stream for QIAGEN. The scale of Brazil's blood screening program - processing 3.5 million samples annually across 14 hemotherapy centers - suggests a substantial and consistent demand for QIAGEN's products.
The long-term nature of this partnership, initiated in 2009 and now expanding, indicates a stable and growing revenue source. This type of ongoing collaboration with a major public health institution can provide predictable cash flows, which are highly valued by investors.
Additionally, QIAGEN's role in supporting over 400 global partners through its Strategic Partnerships & OEM Division demonstrates a diversified business model. This approach can help mitigate risks associated with market fluctuations in any single sector or region, potentially leading to more stable financial performance over time.
Advanced PCR-based screening platform deployed nationwide across 30 laboratories provides new capabilities to detect malaria, HIV, HCV, and HBV in blood donations // Advanced capabilities support epidemiological surveillance of ongoing dengue outbreak in Brazil with unique chemistry developed by QIAGEN and Bio-Manguinhos/Fiocruz // Partnership highlights QIAGEN’s commitment to custom and OEM solutions, technology transfer and long-term support
Venlo, the Netherlands, Rio de Janeiro, Brazil, Sept. 12, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its strategic partnership with Bio-Manguinhos/Fiocruz, the leading provider of vaccines and diagnostics to the Brazilian Ministry of Health. The partnership, initiated in 2009, supported Bio-Manguinhos/Fiocruz with reagents and instruments for testing samples for HIV and hepatitis C virus. With the expansion of this collaboration, Bio-Manguinhos is now able to launch an advanced PCR-based molecular screening platform to detect malaria alongside HIV, hepatitis B and C virus (HCV and HBV), a capability previously unavailable in Brazil’s blood donation program. It also supports epidemiological surveillance of Brazil’s ongoing dengue epidemic by composing Bio-Manguinhos/Fiocruz dengue molecular kits based on unique chemistry developed by QIAGEN and Bio-Manguinhos/Fiocruz. QIAGEN will supply critical molecular biology technologies, custom solutions, and comprehensive training to facilitate Brazil’s public health initiative.
The advanced Brazilian Nucleic Acid Test (NAT Plus) platform, leveraging QIAGEN’s PCR reagents, was recently rolled out as part of Brazil’s national blood screening program. Initiated in 2010, this is the largest blood donation safety initiative in the country’s history. Every year, five million blood donations are performed in Brazil, with
“QIAGEN’s support has been crucial to achieving our public health goals, especially in enabling malaria and dengue screening,” said Antonio Gomes Pinto Ferreira, IVD Reagents Director of Bio-Manguinhos/Fiocruz. “Their team helped us develop and scale an epidemiological solution that significantly enhances our blood screening capabilities and improves public safety.”
“QIAGEN is committed to working side-by-side with technology partners, like Bio-Manguinhos/Fiocruz, to develop high-impact solutions”, said Salim Essakali, Head of Strategic Partnerships & OEM Division at QIAGEN. “This partnership exemplifies how combining QIAGEN’s biotechnology expertise, life science tools and operational capabilities can improve public health outcomes within Brazil’s national blood screening program”.
The NAT Plus platform supports health surveillance within the blood transfusion system, engaging over 300 trained professionals across 14 hemotherapy centers and processing 3.5 million samples annually. Bio-Manguinhos/Fiocruz’s ZCD-typing kit can now also detect and discriminate samples of zika, chikungunya and dengue, and type the latter, which supports epidemiological surveillance programs in Brazil. Under the terms of this agreement, QIAGEN’s solutions will be included in the screening kits and private labeled under the Bio-Manguinhos’s brand.
Since its inception, QIAGENs Strategic Partnerships & OEM Division has supported over 400 global partners in molecular diagnostics, life science research, infectious disease testing, and oncology with state-of-the-art manufacturing facilities, integrated quality management systems and a comprehensive catalogue of customizable products and services.
About QIAGEN Strategic Partnerships
QIAGEN Strategic Partnerships accelerates the process of bringing innovative brands, products, and capabilities to the market by providing tailored solutions and comprehensive support for companies in the life sciences research, biotechnology, and diagnostics sectors. The program offers QIAGEN’s strategic partners access to customized solutions, contract bulk manufacturing, volume packaging, shipping and expert support across all aspects of comprehensive workflows. These workflows include sample preparation, assay development for next-generation sequencing (NGS), precision and custom enzymes, quantitative or digital PCR, bioinformatic analysis solutions, and technical, regulatory, and compliance consultation services. By leveraging QIAGEN’s extensive life science expertise and operational capabilities, strategic partners can develop and deploy high-impact solutions effectively and efficiently.
Learn more about QIAGEN Strategic Partnerships here: https://www.qiagen.com/applications/oem-and-custom-solutions
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of March 31, 2024, QIAGEN employed more than 5,900 people in over 35 locations worldwide. Further information can be found at https://www.qiagen.com.
About Bio-Manguinhos/Fiocruz
Founded in 1976, Bio-Manguinhos is a Fiocruz’s Institute responsible for research, innovation, development and the production of vaccines, in vitro diagnostics and biotherapeutics aimed at primarily meeting the demands of national public health. Bio-Manguinhos/Fiocruz is one of the largest production centers in Latin America, at Fiocruz’ Manguinhos Campus, contributing to the self-sufficiency efforts to supply essential vaccines, biotherapeutics and in vitro diagnostics for the Brazilian Ministry of Health. The Institute also contributes with the public health of several countries, mainly by the export of the yellow fever vaccine, pre-qualified by WHO. Further information can be found at https://www.bio.fiocruz.br/index.php/en-us/bio-eng.
Forward-Looking Statement
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN’s products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, collaborations, markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of QIAGEN’s new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, weather or transportation delays, natural disasters, political or public health crises, and its impact on the demand for our products and other aspects of our business, or other force majeure events; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” contained in Item 3 of our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.
Source: QIAGEN N.V.
Category: Corporate
FAQ
What new capabilities does QIAGEN's collaboration with Bio-Manguinhos/Fiocruz bring to Brazil's blood screening program?
How many laboratories in Brazil are using QIAGEN's NAT Plus platform for blood screening?
What is the annual processing capacity of the NAT Plus platform in Brazil?
How does QIAGEN's technology improve blood transfusion safety in Brazil?
